NRx Pharmaceuticals Q1 Earnings Call Highlights

1 hour ago 3

MarketBeat

Mon, May 18, 2026 astatine 8:05 AM CDT 8 min read

Key Points

Interested successful NRx Pharmaceuticals, Inc.? Here are 5 stocks we similar better.
KETAFREE moved person to a imaginable summertime 2026 support aft the FDA issued mostly insignificant reappraisal comments, and NRx said it has already begun commercialized manufacturing astatine scale. Management believes the merchandise could service some infirmary and ketamine session markets, wherever proviso shortages persist.
NRx said it plans to record an NDA for NRX-100 successful Q2, supported by proceedings information from much than 1,000 patients and real-world grounds from implicit 65,000 patients. The FDA besides indicated it whitethorn see support based connected existing information and broader slump indications, with precedence reappraisal pathways available.
The institution reported a smaller Q1 nett loss of astir $1.4 cardinal versus $5.5 cardinal a twelvemonth earlier, and said it ended the 4th with $6.7 cardinal successful cash. NRx besides said it raised astir $7 cardinal aft quarter-end and expects existent resources to enactment operations done astatine slightest 2026.

5 Biotech stocks tapping into unmet intelligence wellness attraction needs

NRx Pharmaceuticals (NASDAQ:NRXP) said it precocious respective regulatory, manufacturing and objective initiatives during the archetypal 4th of 2026, including advancement toward imaginable support of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100.

Founder, Chairman and Chief Executive Officer Dr. Jonathan Javitt said the 4th was “productive” and contrasted the company’s existent presumption with a twelvemonth earlier, erstwhile helium said NRx had not yet filed for its archetypal cause support and had $8.7 cardinal successful debt. Javitt said the institution is present indebtedness free, has capable currency for contiguous operating needs and raised $7 cardinal aft the extremity of the quarter.

KETAFREE Advances Toward Potential Summer 2026 Approval

→ 3 Crucial Aerospace Component Makers That Analysts Love

Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

Javitt said NRx continued to marque advancement with the FDA reappraisal of KETAFREE, its preservative-free ketamine formulation. In March, the institution said the FDA notified it of a preliminary determination of bioequivalence to the notation branded cause KETALAR. Since then, Javitt said the institution has continued clearing remaining reappraisal disciplines.

According to Javitt, the FDA issued a labeling missive successful April requesting lone insignificant formatting changes and a affirmative subject reappraisal missive connected prime that requested administrative changes the bureau identified arsenic minor. He said enactment of the FDA Office of Generic Drugs expressed enactment for addressing remaining items wrong the existent reappraisal cycle, accordant with the company’s extremity of summertime 2026.

Read Entire Article